Qianjin Pharmaceutical: Subsidiary Obtains Four Drug Registration Certificates

Qianjin Pharmaceutical announced that its subsidiaries, Qianjin Xiangjiang Pharmaceutical and Qianjin Xieli Pharmaceutical, have received drug registration certificates approved and issued by the National Medical Products Administration for Minoxidil topical solution, Ezetimibe tablets, Amlodipine Benazepril capsules, and Ursodeoxycholic acid capsules. Among them, Qianjin Xiangjiang Pharmaceutical is the marketing authorization holder for Minoxidil topical solution and Ezetimibe tablets, with corresponding cumulative R&D investments of 5.6273 million yuan and 5.5431 million yuan, respectively; Qianjin Xieli Pharmaceutical is the marketing authorization holder for Ursodeoxycholic acid capsules and Amlodipine Benazepril capsules, with corresponding cumulative R&D investments of 9.7997 million yuan and 1.7286 million yuan.